How Common Is Mast Cell Activation Syndrome?

Nobody can give a clean, single number for how common mast cell activation syndrome is, because the answer depends almost entirely on which set of diagnostic criteria you use. At one end, a study of over 700 patients referred to a specialist center for suspected mast cell problems found that only about 4% met strict consensus criteria for idiopathic MCAS. At the other end, researchers using broader, alternative criteria have estimated prevalence as high as 17% of the general population. That gap is not a rounding error. It reflects one of the most contentious debates in allergy and immunology right now, and it has real consequences for patients trying to get diagnosed.

What MCAS Actually Involves

Mast cells are immune cells found throughout your body, concentrated in tissues that interact with the outside world: skin, gut lining, airways. When they activate, they dump chemical mediators like histamine, prostaglandins, and tryptase into surrounding tissue. In a healthy person, this is how you mount a response to a bee sting or a pathogen. In MCAS, these cells fire off inappropriately or excessively, producing symptoms that can hit multiple organ systems at once. Common complaints include flushing, hives, low blood pressure, headaches, vomiting, and diarrhea.¹

What makes MCAS particularly frustrating, for patients and doctors alike, is that none of these symptoms are unique to it. Flushing can come from menopause, anxiety, or a glass of wine. Diarrhea and abdominal pain overlap with irritable bowel syndrome. Hives can be chronic and idiopathic. The challenge is distinguishing a pattern of mast cell overactivity from dozens of other conditions that produce the same individual complaints.

The Diagnostic Criteria War

The heart of the prevalence question is a disagreement among experts about what should count as MCAS. Under the consensus criteria developed by a group of international mast cell specialists, diagnosis requires three things: typical clinical symptoms involving two or more organ systems, a meaningful rise in serum tryptase during a symptomatic episode compared to the patient’s personal baseline, and improvement with treatments that target mast cell mediators.² All three must be present. The tryptase requirement is the gatekeeping step: you need a blood draw during or shortly after a flare that shows tryptase climbing at least 20% plus 2 ng/mL above your baseline.

A separate group of researchers has proposed alternative criteria that are less strict about the lab evidence. Under these alternative frameworks, a wider range of mediator tests can satisfy the laboratory requirement, and some versions lean more heavily on symptom patterns and treatment response. These alternative criteria have been criticized for lacking specificity and validation.³ The concern is straightforward: if your diagnostic net is wide enough, you will catch people who do not actually have a mast cell problem.

A 2024 study used large language models to cluster the symptom profiles associated with each set of criteria and found that the alternative criteria were associated with a distinct and broader group of diagnoses compared to the consensus criteria. The authors concluded that the alternative criteria had lower diagnostic consistency and could contribute to overdiagnosis, potentially causing patients to miss the real underlying condition.⁴

What the Prevalence Numbers Actually Mean

The 17% figure, sometimes cited in the medical literature, traces back to researchers who use the broader alternative criteria and who view MCAS as a common but underrecognized condition.⁵ Under this view, a large fraction of people with unexplained chronic multi-system symptoms might actually have dysfunctional mast cells driving their illness. If true, that would make MCAS one of the most common chronic conditions nobody has heard of.

The 4.4% figure comes from a very different setting. Researchers at a specialist center evaluated 703 patients who had been referred specifically because mast cell disease was suspected. Even within this pre-selected group, only 31 met the strict consensus criteria for idiopathic MCAS, leading the authors to conclude that it is an uncommon condition.⁶ Keep in mind that 4.4% of a referred population is much lower than 4.4% of the general population. These were people already flagged as possible mast cell cases. The true general-population prevalence under consensus criteria would be substantially lower than that.

So you have estimates spanning roughly two orders of magnitude. The honest assessment: using consensus criteria, MCAS appears to be genuinely rare. Using alternative criteria, it appears common. Which criteria are correct is the question the field has not resolved, and your experience navigating the medical system will depend heavily on which camp your doctor falls into.

The Overdiagnosis Problem

The stakes of this diagnostic disagreement are higher than an academic turf war. A recent review argued that the less specific laboratory tests sometimes used under alternative frameworks can lead to widespread overdiagnosis. Patients labeled with MCAS who do not actually have it often do not respond to standard mast cell therapies, end up with reduced quality of life, and face social stigmatization. Worse, the MCAS label can obscure whatever condition is actually causing their symptoms, meaning they never receive appropriate treatment.⁷

This is a genuinely difficult clinical problem. On one side, there are patients who have spent years searching for an explanation for debilitating symptoms that span multiple organ systems. An MCAS diagnosis can feel like a lifeline, especially when previous doctors have dismissed their complaints. On the other side, a diagnosis that is not specific enough can become a catch-all bin, and that helps nobody long-term. Some clinicians report seeing patients who arrive having already self-diagnosed via social media, which adds another layer of complexity to the evaluation.

How MCAS Differs from Systemic Mastocytosis

MCAS exists within a broader family of mast cell diseases. The umbrella term covers three main conditions: systemic mastocytosis, MCAS, and the extremely rare mast cell leukemia.⁸ In systemic mastocytosis, the problem is that mast cells accumulate abnormally in organs, particularly bone marrow, and typically carry a specific genetic mutation called KIT D816V. The World Health Organization has established clear pathological criteria for this diagnosis, and a bone marrow biopsy can confirm it.

MCAS is defined more by what it is not: the patient has mast cell mediator symptoms, but does not meet the criteria for systemic mastocytosis. Under the consensus classification system, MCAS itself breaks down into three subtypes. Primary MCAS involves clonal mast cells carrying the KIT mutation but still falling short of full systemic mastocytosis. Secondary MCAS is driven by an identifiable underlying disease, most commonly an IgE-mediated allergy. Idiopathic MCAS is the diagnosis when neither clonal cells nor an underlying trigger can be found.⁹ The idiopathic form is what most people mean when they refer to MCAS in casual conversation, and it is the subtype at the center of the prevalence debate.

Among patients with confirmed systemic mastocytosis, the vast majority have the indolent form, which is manageable and generally has a normal life expectancy. One cohort of 116 confirmed patients found that about three-quarters had indolent disease.¹⁰ The aggressive subtypes are uncommon even within an already uncommon disease.

The Triad with Hypermobility and POTS

Online patient communities have long discussed a triad of MCAS, hypermobile Ehlers-Danlos syndrome, and postural orthostatic tachycardia syndrome. The idea is that these three conditions travel together, possibly sharing a common underlying mechanism. Clinicians have noticed that patients presenting with one of these diagnoses frequently report symptoms consistent with the other two.

A systematic review of this proposed relationship found that the evidence for a genuine link is weak. The authors concluded that studies proposing a relationship between the three conditions were either biased or based on outdated diagnostic criteria, and that the apparent association stems from an overlapping pool of vague, subjective symptoms rather than a shared pathological mechanism.¹¹ That does not mean the association is impossible, but it does mean the evidence so far has not been strong enough to confirm it as a real biological relationship rather than a diagnostic artifact.

Separately, hereditary alpha-tryptasemia, a genetic trait involving extra copies of the tryptase gene, was initially thought to tie into this triad. More recent work has reframed it as a common genetic modifier of mast cell reactions rather than a disorder in its own right. Some of its previously assumed associations with connective tissue abnormalities and autonomic dysfunction have not held up in newer studies, though its connection to both clonal and nonclonal mast cell disorders appears more solid.¹²

MCAS and Long COVID

The COVID-19 pandemic brought renewed attention to MCAS. Researchers observed that the symptom profiles of long COVID and MCAS overlap considerably: fatigue, brain fog, flushing, gastrointestinal problems, heart rate irregularities, and a relapsing-remitting pattern. Both conditions also seem to improve with some of the same treatments, including antihistamines and mast cell stabilizers.¹³

One proposed mechanism is that SARS-CoV-2 infection triggers excessive mast cell activation, either by worsening a pre-existing but undiagnosed MCAS or by inappropriately activating normal mast cells through persistent viral particles or ongoing inflammation.¹⁴ There are published case reports of patients who developed both POTS and MCAS after COVID-19 infection, with evidence of immune dysregulation persisting more than a year after the initial illness.¹⁵

Whether long COVID is literally MCAS or merely shares some downstream pathways remains unresolved. Mast cells are activated in many inflammatory states, and finding activated mast cells in long COVID does not automatically mean the patient has MCAS as a distinct condition. But the overlap has been productive in one sense: it has directed researchers toward mast cell stabilization as a treatment strategy worth testing in long COVID, regardless of the diagnostic label.

How Mast Cells Get Triggered

The classic image of mast cell activation involves IgE antibodies binding to allergens, which is the standard allergy pathway. But mast cells can be activated through many non-allergic routes, including complement proteins, neuropeptides, certain drugs, and even physical stimuli like temperature changes and vibration.¹⁶ This helps explain why MCAS patients often report flares in response to triggers that have nothing to do with traditional allergies: stress, heat, exercise, or fragrances.

Recent research has focused on a receptor called MRGPRX2, which gives mast cells the ability to respond to a wide array of stimuli that bypass the IgE pathway entirely. This receptor is involved in non-histamine-mediated itch, pain, and drug-induced pseudoallergic reactions.¹⁷ For MCAS patients, the relevance is that their trigger list can be bewilderingly long and seemingly random, because the underlying biology supports many different activation pathways.

Treatment Approaches

Regardless of which diagnostic criteria were used, the treatment strategy for MCAS follows a fairly consistent stepwise approach. First-line therapy involves blocking the effects of mast cell mediators using H1 antihistamines (like cetirizine or loratadine) and H2 antihistamines (like famotidine), often combined with leukotriene receptor blockers and mast cell stabilizers such as cromolyn sodium.¹⁸ Many patients find that some combination of these over-the-counter and prescription medications significantly reduces flare frequency and severity.

In a systematic review of antihistamine use in primary mast cell activation syndromes, one trial found that the H1 antihistamine rupatadine improved quality of life and controlled symptoms including itching, flushing, and rapid heart rate compared to placebo, though gastrointestinal symptoms were less responsive.¹⁹ The trial evidence for antihistamines in MCAS specifically is thinner than you might expect for such a commonly prescribed treatment, partly because the condition has only recently been formally defined.

Some patients require higher-than-standard doses of cromolyn sodium. A recent case series reported that five patients with both MCAS and chronic fatigue syndrome benefited from a cromolyn dose of 1,600 to 2,400 mg daily, well above the typical recommendation but still within FDA safety guidelines.²⁰

For patients who do not respond adequately to first-line therapy, omalizumab, originally developed for severe allergic asthma, has shown promise. A systematic review of omalizumab in refractory MCAS found that most patients experienced at least a partial reduction in symptoms, and a subset achieved a complete response. Higher doses appeared to be associated with better outcomes, and some patients were able to stop systemic corticosteroids after starting omalizumab.²¹ One case report documented a sustained response over five years with low-dose omalizumab, which also allowed the patient to resume bee venom immunotherapy that had previously been impossible.²²

The Cost of Delayed Diagnosis

Whatever the true prevalence turns out to be, one consistent finding is that patients who eventually receive an MCAS diagnosis have often spent years bouncing between specialists without answers. Survey data from The Mast Cell Disease Society showed that patients whose diagnosis was delayed two years or more reported worse outcomes across physical, emotional, and cognitive health measures, including fatigue, pain, and brain fog, compared to those diagnosed earlier.²³ Because MCAS symptoms mimic many other chronic conditions, patients are frequently diagnosed with irritable bowel syndrome, chronic urticaria, anxiety, or other individual conditions before someone considers the possibility that a single process might be connecting the dots.

This creates a paradox at the heart of the prevalence debate. Strict criteria reduce overdiagnosis but risk leaving real MCAS patients without a diagnosis for years. Loose criteria speed up recognition but risk labeling patients with a condition they do not have, potentially delaying the correct diagnosis just as effectively. Neither extreme serves patients well, which is why the field’s ongoing work to refine diagnostic biomarkers and validation studies matters so much.

MCAS in Children

Mast cell diseases in children look different from adult presentations. More than half of mastocytosis patients are children, and the pediatric form tends to be limited to the skin rather than involving bone marrow or internal organs. It typically appears in the first months of life and frequently resolves spontaneously by adolescence.²⁴ Children with mastocytosis do experience mast cell activation symptoms, ranging from itching to flushing and blistering, but the prognosis is generally much better than for adults diagnosed with systemic disease.

MCAS as a standalone diagnosis in children is less well studied, and most of the prevalence debate centers on adults. When children present with monomorphic skin lesions resembling the adult pattern, that is considered a warning sign that the disease may persist into adulthood rather than resolve. The treatment approach for children mirrors the adult strategy, with antihistamines and mast cell stabilizers forming the backbone, but the overall trajectory tends to be more favorable.